We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
+21.7%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$543M
AUM Growth
-$76.7M
(-12%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-21.88%
Top 10 Holdings %
Top 10 Hldgs %
99.78%
Holding
17
New
5
Increased
3
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$42.3M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$31.3M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$9.65M |
| 4 |
Invivyd
IVVD
|
+$3.21M |
| 5 |
Vir Biotechnology
VIR
|
+$1.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$168M |
| 2 |
Beam Therapeutics
BEAM
|
+$16.3M |
| 3 |
EPIX
ESSA Pharma
EPIX
|
+$5.96M |
| 4 |
BridgeBio Pharma
BBIO
|
+$4.46M |
| 5 |
VERV
Verve Therapeutics
VERV
|
+$4.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma
XLRN
| $344M | 63.36% |
2,000,000
+239,654
| +14% | +$31.3M |
|
|
2
Intellia Therapeutics
NTLA
$1.59B
| $101M | 18.57% |
752,024
-1,107,902
| -60% | -$168M |
|
|
3
BioNTech
BNTX
$23.1B
| $36.3M | 6.68% |
+132,932
| New | +$42.3M |
|
4
Fate Therapeutics
FATE
$324M
| $20.9M | 3.85% |
353,250
+17,332
| +5% | +$1.36M |
|
|
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $18.1M | 3.33% |
542,586
+317,106
| +141% | +$9.65M |
|
|
6
BridgeBio Pharma
BBIO
$15.9B
| $11.9M | 2.19% |
253,692
-83,125
| -25% | -$4.46M |
|
|
7
Invivyd
IVVD
$219M
| $3.65M | 0.67% |
+86,528
| New | +$3.21M |
|
8
Aclaris Therapeutics
ACRS
$793M
| $2.87M | 0.53% |
159,393
-90,607
| -36% | -$1.45M |
|
|
9
Vir Biotechnology
VIR
$1.59B
| $1.97M | 0.36% |
+45,311
| New | +$1.96M |
|
|
VERV
10
DELISTED
Verve Therapeutics
VERV
| $1.29M | 0.24% |
27,397
-75,616
| -73% | -$4.45M |
|
11
Fulcrum Therapeutics
FULC
$243M
| $959K | 0.18% |
+33,997
| New | +$644K |
|
|
JBIO
12
Jade Biosciences
JBIO
$1.27B
| $262K | 0.05% |
+357
| New | +$200K |
|
|
13
Beam Therapeutics
BEAM
$2.83B
| – | – |
-126,985
| Closed | -$16.3M |
|
|
EPIX
14
DELISTED
ESSA Pharma
EPIX
| – | – |
-208,524
| Closed | -$5.96M |
|
|
GBIO
15
DELISTED
Generation Bio
GBIO
| – | – |
-1,074
| Closed | -$289K |
|
16
Keros Therapeutics
KROS
$211M
| – | – |
-104,186
| Closed | -$4.42M |
|
17
Relay Therapeutics
RLAY
$4.34B
| – | – |
-119,775
| Closed | -$4.38M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q3 2021 Portfolio in Review
As of Q3 2021, Darwin Global Management held 17 positions worth $543M, down 12% from $620M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Darwin Global Management withdrew a net $119M in Q3 2021, closing 5 positions and reducing 4 holdings. Its most notable exit was Beam Therapeutics, an estimated $16.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Darwin Global Management opened a new position in BioNTech worth $36.3M.
- Darwin Global Management's largest Q3 2021 buy was BioNTech: 132,932 shares worth $36.3M.
- Darwin Global Management added most to Acceleron Pharma in Q3 2021, an estimated $31.3M increase.
- Darwin Global Management's biggest Q3 2021 reduction was Intellia Therapeutics, cutting an estimated $168M.
- Darwin Global Management fully exited Beam Therapeutics in Q3 2021, selling an estimated $16.3M.
- Darwin Global Management's ten largest holdings make up 100% of its $543M portfolio in Q3 2021.
- Darwin Global Management opened 5 new positions and closed 5 in Q3 2021.
- Darwin Global Management's portfolio value fell 12% quarter-over-quarter to $543M.
Based on Darwin Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.